

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice Number: 1512/1612 – June 2012

Nevirapine (Viramune®)

Limited submission by Boehringer Ingelheim Ltd

Recommendation of the All Wales Medicines Strategy Group

Nevirapine (Viramune®) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets.

Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used.

Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing.

Additional note(s):

- AWMSG of the opinion that nevirapine (Viramune®) prolonged release tablets may be appropriate for specialist only prescribing within NHS Wales for the indication under consideration.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (Adults), AWMSG Secretariat Assessment Report (Adolescents and children), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (Adults), clinical expert opinion (Adolescents and children), lay/patient/carer perspective and discussions at AWMSG.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in December 2022. No new evidence was identified that is likely to significantly affect the current recommendation.

Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
1512/1612: Nevirapine (Viramune®) June 2012